Revance proving volatile

|About: Revance Therapeutics, ... (RVNC)|By:, SA News Editor

Revance (RVNC) continues its volatile ways following its IPO on February 6, when it debuted at $16. The stock is up 2.5% today at $27.61 but that's down sharply from earlier highs and follows a steep fall at the end of last week.

Revance's lead product is a topical Botulinum Toxin Type A Gel for the treatment of lateral canthal lines (crow's feet). It will complete with Allergan's (AGN) blockbuster injectable treatment Botox.

Botulinum is in Phase 3 trials in the U.S.

Anaylsts' price targets range from $37-55.